In Phase 3, 48-week studies of CF patients (pts) with the G551D mutation, ivacaftor provided benefits, including improved lung function, sweat chloride and fewer pulmonary exacerbations (PEs). We analyzed data from Studies 102/103 to better understand the clinical diagnosis and treatment of PEs. In Studies 102 ( 12 yrs, N = 161) and 103 (6−11 yrs, N = 52) a change in antibiotic therapy for any of 12 protocol-defined signs or symptoms was called a sinopulmonary event (SPE). SPEs with 4 signs or symptoms were defined as a PE. Over 48 weeks, there were 146 PEs in 72 pts ( 12 yrs) and 12 PEs in 11 pts (6−11 yrs). PEs and SPEs are summarized in the Tables. Pts treated with ivacaftor had fewer PEs and SPEs than controls. Although young pts (6−11 yrs) experienced fewer PEs overall, the percentage of young pts having SPEs was comparable to the older pts. In older pts ( 12 yrs), the 4 most frequently reported signs or symptoms were consistent across the ivacaftor and placebo groups. Pts treated with ivacaftor in Study 102 had fewer reported protocol-defined signs or symptoms than controls. We recently published the first description of correction of a CF causing mutation (DF508) in a tracheal epithelial cell line by homology directed repair (HDR) using zinc finger nucleases (ZFNs) and a donor plasmid (Lee et al., 2012) . At present the approach is limited to correcting one mutation. To address this, we are using our existing cftr-specific ZFNs to target a cftr mini-gene to intron 9 with the aim to correct CF mutations throughout exons 10−24 (~80% of all CF mutations) with a single ZFN pair/donor plasmid. As proof-of-principle that our ZFNs can target exogenous sequences to intron 9 we first sought to precisely incorporate a 7 bp Tag sequence into the cftr gene at the ZFN target site by HDR using a 1.5 kb donor plasmid. Analysis of cells treated with our ZFNs and donor by nested PCR revealed that the Tag can be successfully introduced into the cftr gene at the correct location.
To effect gene repair, the mini-gene repair construct requires a promoterless cftr partial cDNA (exons 10−24) with appropriate splice acceptor and poly A sites. Incorporation of the mini-gene would result in full length corrected CFTR mRNA production that is under the control of the endogenous promoter, a major limitation experienced when delivering exogenous cDNA. Li et al., 2011, previously replaced exons 2−8 of the F9 gene restoring haemostasis in haemophilic mice using this strategy. Successful gene correction using a mini-gene would result in normal spatiotemporal expression of the corrected CFTR gene, that is permanent for the lifetime of the cell and is not subject to gene silencing. It could be of use as an alternative strategy to cDNA addition for gene therapy.
